Affimed Debt to Equity Ratio 2014-2024 | AFMDQ
Current and historical debt to equity ratio values for Affimed (AFMDQ) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Affimed debt/equity for the three months ending September 30, 2024 was 0.13.
| Affimed Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-09-30 |
$0.03B |
$0.02B |
1.32 |
| 2024-06-30 |
$0.03B |
$0.03B |
0.85 |
| 2024-03-31 |
$0.03B |
$0.04B |
0.74 |
| 2023-12-31 |
$0.04B |
$0.06B |
0.68 |
| 2023-09-30 |
$0.05B |
$0.08B |
0.58 |
| 2023-06-30 |
$0.04B |
$0.11B |
0.36 |
| 2023-03-31 |
$0.05B |
$0.13B |
0.34 |
| 2022-12-31 |
$0.05B |
$0.16B |
0.31 |
| 2022-09-30 |
$0.06B |
$0.18B |
0.31 |
| 2022-06-30 |
$0.07B |
$0.21B |
0.35 |
| 2022-03-31 |
$0.09B |
$0.13B |
0.65 |
| 2021-12-31 |
$0.11B |
$0.16B |
0.66 |
| 2021-09-30 |
$0.10B |
$0.16B |
0.65 |
| 2021-06-30 |
$0.12B |
$0.18B |
0.64 |
| 2021-03-31 |
$0.12B |
$0.20B |
0.60 |
| 2020-12-31 |
$0.12B |
$0.08B |
1.44 |
| 2020-09-30 |
$0.07B |
$0.06B |
1.30 |
| 2020-06-30 |
$0.07B |
$0.05B |
1.50 |
| 2020-03-31 |
$0.07B |
$0.03B |
2.11 |
| 2019-12-31 |
$0.08B |
$0.04B |
1.91 |
| 2019-09-30 |
$0.07B |
$0.03B |
2.85 |
| 2019-06-30 |
$0.07B |
$0.04B |
2.02 |
| 2019-03-31 |
$0.08B |
$0.05B |
1.59 |
| 2018-12-31 |
$0.09B |
$0.05B |
1.90 |
| 2018-09-30 |
$0.02B |
$0.04B |
0.37 |
| 2018-06-30 |
$0.02B |
$0.06B |
0.26 |
| 2018-03-31 |
$0.02B |
$0.07B |
0.23 |
| 2017-12-31 |
$0.01B |
$0.04B |
0.37 |
| 2017-09-30 |
$0.01B |
$0.04B |
0.34 |
| 2017-06-30 |
$0.01B |
$0.04B |
0.33 |
| 2017-03-31 |
$0.01B |
$0.05B |
0.20 |
| 2016-12-31 |
$0.01B |
$0.04B |
0.26 |
| 2016-09-30 |
$0.01B |
$0.05B |
0.23 |
| 2016-06-30 |
$0.01B |
$0.06B |
0.17 |
| 2016-03-31 |
$0.01B |
$0.07B |
0.18 |
| 2015-12-31 |
$0.01B |
$0.08B |
0.18 |
| 2015-09-30 |
$0.01B |
$0.06B |
0.18 |
| 2015-06-30 |
$0.01B |
$0.07B |
0.16 |
| 2015-03-31 |
$0.01B |
$0.04B |
0.28 |
| 2014-12-31 |
$0.01B |
$0.04B |
0.32 |
| 2014-09-30 |
$0.01B |
$0.05B |
0.27 |
| 2014-06-30 |
$0.00B |
|
0.00 |
| 2014-03-31 |
$0.00B |
|
0.00 |
| 2013-09-30 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
